Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Authors:
- Agam K. RaoARAgam K. Rao
- Faisal S. MinhajFMFaisal S. Minhaj
- Rosalind J. CarterRCRosalind J. Carter
- Jonathan DuffyJDJonathan Duffy
- Panayampalli S. SatheshkumarPSPanayampalli S. Satheshkumar
- Kevin P. DelaneyKDKevin P. Delaney
- Laura A. S. QuilterLQLaura A. S. Quilter
- Rachel E. KachurRKRachel E. Kachur
- Catherine McLeanCMCatherine McLean
- Danielle L. MouliaDMDanielle L. Moulia
- David T. KuharDKDavid T. Kuhar
- Marie A. de PerioMPMarie A. de Perio
Open Access
- 19 June 2025
- journal article
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 74 (22) , 385-392
Abstract
This report describes ACIP’s 2023 recommendation for JYNNEOS vaccine use in people 18 years and older who are at risk for mpox during an mpox outbreak.Keywords
This publication has 21 references indexed in Scilit:
- MVA-BN third-dose 5 years after primary; Democratic Republic of the CongomedRxiv, 2025
- Modeling the impact of vaccine dose prioritization strategies during the 2022 mpox outbreakAmerican Journal of Epidemiology, 2025
- Epidemiological and genomic evolution of the ongoing outbreak of clade Ib mpox virus in the eastern Democratic Republic of the CongoNature Medicine, 2025
- How did the 2022 global mpox outbreak happen? A travel-associated case 6 months earlier may provide important cluesTravel Medicine and Infectious Disease, 2023
- Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United StatesNew England Journal of Medicine, 2023
- Multiple lineages of monkeypox virus detected in the United States, 2021–2022Science, 2022
- Emergence of Monkeypox — West and Central Africa, 1970–2017MMWR. Morbidity and Mortality Weekly Report, 2018
- Prevalence of Immunosuppression Among US Adults, 2013JAMA, 2016
- Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic DermatitisPLOS ONE, 2015
- Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitisVaccine, 2014